Health Economics›Diffuse large B-cell lymphoma›Relapsed or refractory salvage therapy

Relapsed or refractory salvage therapy

Diffuse large B-cell lymphoma · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
O-ICE Variant #01	—	R 1 549 559	21d	—	—	—	—	—
O-DHAP Variant #01	—	R 1 540 771	21d	—	—	—	—	1
Glofit-GemOx Variant #01	—	R 224 572	21d	—	25.5 mo	—	—	1
R-DHAOx Variant #02	—	R 51 858	21d	—	—	—	—	—
R-ICE Variant #01	—	R 46 927	21d	—	31.1 mo	—	—	1
R-DHAP/R-VIM Variant #01	—	R 39 673	28d	—	—	—	—	—
R-DexaBEAM Variant #01 Partial	—	R 25 792	28d	—	—	—	—	—
R-NIMP Variant #01	—	R 25 249	28d	—	—	—	—	—
RICER Variant #01	—	R 25 150	14d	—	—	—	—	—
R-DHAP Variant #06	—	R 17 673	21d	—	31.1 mo	—	—	2
R-GemOx Variant #04	—	R 16 789	21d	3.8 mo	12.9 mo	6	R 100 734 PFS proxy	2
DHAP/VIM Variant #01	—	R 16 081	28d	—	—	—	—	—
R-IFE Variant #01	—	R 15 682	14d	—	—	—	—	—
R-ESHAP Variant #01	—	R 15 462	—	—	31.1 mo	—	—	1
R-GDP Variant #01	—	R 15 361	21d	—	31.1 mo	—	—	1
HAM Variant #01	—	R 13 754	—	—	—	—	—	—
R-EPOCH Variant #01	—	R 13 350	21d	—	—	—	—	—
VIPD Variant #03	—	R 11 450	21d	—	—	—	—	—
EPIC (cisplatin) Variant #01	—	R 11 188	21d	—	—	—	—	—
EPIC (carboplatin) Variant #01	—	R 11 070	21d	—	—	—	—	—
DHAP Variant #01	—	R 3 777	28d	—	—	—	—	—
MINE N/A - secondary systemic drug	—	R 2 064	28d	—	—	—	—	—
Axicabtagene ciloleucel monotherapy N/A - secondary systemic drug	—	R 0	—	—	—	—	—	1
Lisocabtagene maraleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—

24 of 24 regimens shown